Profusa, Inc. said Nasdaq has closed its review after determining the company complied with the requirement for at least 500,000 publicly held shares. The shortfall occurred on August 14, 2026, after the effectiveness of Profusa's 1-for-4 reverse stock split, but the company restored compliance by August 21, 2026, based on correspondence with Nasdaq. The notice does not affect the listing or trading of Profusa securities, which remain on The Nasdaq Capital Market under the symbol PFSA. Nasdaq Listing Rule 5810(b) requires prompt public disclosure of deficiency notifications. Berkeley, California-based Profusa is developing tissue-integrated sensors and a data platform intended to provide continuous, medical-grade biochemical data for personal and medical use. The company cautioned that statements about the timing and completion of the reverse split and other future events are forward-looking and subject to risks and uncertainties.